News

NSF Awards NOVA’s Biotechnology Program $550,000 for NOBLE Project

The NOVA Biotechnology and Leadership in Education (NOBLE) Project will be funded by the National Science Foundation with more than $550,000 over the next three years. The goal of the NOBLE Project is to revitalize and grow the biotechnology program. The NOBLE Project seeks to recruit students throughout the entire NOVA service area, particularly minorities in STEM, veterans and dual-enrollment students. The NOBLE Project will include faculty from the Alexandria and Manassas campuses.

The goal of the NOBLE Project is to train students in technical and professional skills to increase their competitiveness in the biotechnology job market. Students will gain additional key experiences by attending scientific conferences and connecting with scientific organizations. Importantly, the grant will provide funds for paid internships at local biotechnology companies. Work will begin this summer. Interested students should contact Xin Zhou at xzhou@nvcc.edu or David Fernandez at dfernandez@nvcc.edu.

The principle investigator (PI) of this project, Dr. David Fernandez, thanks Dr. Eun-Woo Chang, vice president of academic affairs and chief academic office; Dr. Xin Zhou, NOVA biotechnology program head; Dr. Maggie Emblom-Callahan, interim dean of MSTB Alexandria and Dr. Diane Mucci, Annandale Campus provost, for their guidance and vision in crafting this project.

Recent News

03/12/2026

Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 lotion (4%) for the treatment of Netherton Syndrome, a rare

03/11/2026

ATCC Secures NIAID Contract to Strengthen U.S. Preparedness Against Emerging Infectious Diseases

ATCC has been awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract (number 75N93025D00017) with an ordering period of 7 years with Federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), an institute within the National Institutes of Health (NIH) and the Department of Health and Human Services (HHS). The contract, with an initial

03/10/2026

ivWatch and Aon Address Costly and Underreported Patient Harm Epidemic with New Return on Investment Model

ivWatch, the IV safety company, has partnered with Aon, a leading global insurance broker and risk consultant, to quantify the clinical and financial impact of severe IV infiltration and extravasation injuries – one of the most underreported and costly adverse events in healthcare – and to model the return on investment associated with detecting these